Navigation Links
Pieris Presents Preclinical Data for PRS-080 Hepcidin Antagonist Anticalin(R) Program at ASH Annual Meeting

SAN DIEGO, California, December 13, 2011 /PRNewswire/ --

-- Breadth of Pharmacokinetic Data Points to Tunable Half-life for Platform --

Pieris AG presented novel preclinical in vitro and in vivo data for its PRS-080 Anticalin hepcidin antagonist in an oral presentation at the American Society of Hematology Annual Meeting, the company announced today.  In a presentation entitled "Discovery and Preclinical Characterization of a Novel Hepcidin Antagonist with Tunable PK/PD Properties for the Treatment of Anemia in Different Patient Populations", the results demonstrated Pieris' PRS-080's ability to increase the serum iron levels in preclinical models by binding the hepcidin target with high affinity and specificity, while offering the flexibility of a tunable pharmacokinetic (PK) and pharmacodynamic (PD) profile.

"These studies in multiple preclinical species and models demonstrate the high level of control offered by the Anticalin approach in combination with PEGylation to create 'fit for purpose' PK/PD profiles that can match specific target biology across different patient populations," stated Laurent Audoly, Ph.D., Chief Scientific Officer of Pieris.  "In particular, the clear relationship between PEG formats and the resulting PK/PD profile for several PRS-080 variants tested in animal models provides an extremely encouraging basis for a rapid advance toward the clinic and creates a portfolio of molecules adapted for different hepcidin-dependent diseases."

The presentation at ASH included several in vivo animal studies of PRS-080's sub-nanomolar potency in binding hepcidin, which is a small peptide that plays a pivotal role in the regulation of iron levels in the blood.  In addition, Pieris researchers documented reliable drug half-life levels dependent on the size of the PEGylated compound.  In several preclinical models, a single dose of four different formulations of PRS-080 showed clear correlation between the PEGylation size and the pharmacokinetic properties.  Based on these data and the clinical experience from a recently completed Phase I trial with a separate compound, PRS-050, Pieris researchers predict a high level of confidence in defining the best half-life profile for treating anemia in patients.  The lead PRS-080 program candidate is projected to enter human clinical trials in the first half of 2013.

Hepcidin is a liver-derived peptide that regulates iron homeostasis in the blood. Produced in response to iron overload and inflammation, hepcidin decreases iron absorption.  When over-expressed, the peptide is associated with the development of anemia, often the result of chronic kidney disease, cancer, cancer treatments such as chemotherapy, and other inflammatory diseases.

Anticalins are therapeutic proteins derived from human lipocalins, rationally engineered to solve for the pharmacological and pharmaceutical limitations of both protein and non-protein based drug platforms.

About Pieris

Pieris AG is an independent, clinical-staged biotechnology company advancing its proprietary Anticalin® technology to create differentiated drugs that are safer and more effective than conventional approaches.  Exclusive to Pieris, Anticalin-based drugs promise to address high-unmet medical needs and expand the therapeutic potential of current targeted approaches.  Pieris' pipeline ranges from its lead compound, PRS-050 (anti-VEGF, oncology) that recently completed a Phase I clinical trial, to multiple Anticalins in preclinical development across a range of therapeutic areas.  The company has four ongoing discovery and development collaborations: Daiichi Sankyo, Takeda San Francisco, the Sanofi Group and Allergan.  Privately held, Pieris has been funded by premier biotechnology-focused venture capital, including lead investors OrbiMed Advisors and Global Life Science Ventures. For more information, please visit:


For further information, please contact:

Dr. Andreas Hohlbaum
Vice President, Strategic Research and Project Management
Pieris AG
Gretchen Schweitzer

Additional information is available at

Anticalin®, Anticalins® are registered trademarks of Pieris AG.

Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Wacker Validates Scalability of Anticalin(R) Production With E.coli Secretion Technology and Will Produce Pieris First Clinical Candidate PRS-050
2. Pieris Reports Development Progress for Anticalin(R) PRS-050, a Next Generation VEGF Antagonist
3. Pieris Announces Results and Successful Completion of its PRS-050 Anticalin Phase I Trial at AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference
4. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
5. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
6. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
7. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
8. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
9. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
10. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
11. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
Post Your Comments:
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
(Date:6/23/2016)... 23, 2016  In a startling report released today, National ... by lacking a comprehensive, proven plan to eliminate prescription opioid overdoses. ... of how states are tackling the worst drug crisis in recorded ... – Kentucky , New Mexico ... . Of the 28 failing states, three – Michigan ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... Those ... deal with these feelings, many turn to unhealthy avenues, such as drug or alcohol ... of Marne, Michigan, has released tools for healthy coping following a traumatic event. , ...
(Date:6/24/2016)... ... , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys ... peers for this recognition are considered among the top 2 percent of lawyers practicing ... members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. ...
(Date:6/24/2016)... ... 2016 , ... People across the U.S. are sharpening their pencils and honing ... contest in which patients and their families pay tribute to a genetic counselor by ... Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, LLC ... by obtaining investment capital for emerging technology companies. SCP has delivered investment ... resulted in more than a million dollars of capital investment for five companies. ...
Breaking Medicine News(10 mins):